Liver-Targeted PCSK9 siRNA Conjugate for LDL-C Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia, particularly high levels of low-density lipoprotein cholesterol (LDL-c), are inadequate for many patients, and there is a need for effective methods to inhibit the expression of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene to manage lipid metabolism and reduce cardiovascular risk.
Innovation Solution
Development of an siRNA conjugate specifically targeting the liver to inhibit PCSK9 gene expression, comprising a sense and antisense strand with modified nucleotides and a conjugation group, formulated in a pharmaceutical composition for effective delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional lipid-lowering medicines are used, then plasma cholesterol levels can be reduced, but a considerable proportion of patients fail to achieve desired lipid levels
Solution Approach 1:
The patent uses PCSK9 as an intermediary target to achieve better cholesterol control. Instead of directly targeting cholesterol absorption or synthesis pathways (which have limited efficacy), the invention mediates the effect through PCSK9 inhibition, thereby enhancing LDL receptor activity and achieving superior lipid-lowering effects that conventional medicines cannot provide
Solution Approach 2:
The patent employs siRNA technology to fundamentally change the parameter of PCSK9 expression at the mRNA level. By introducing small interfering RNA that specifically targets and degrades PCSK9 mRNA, the invention achieves a quantitative reduction in PCSK9 protein expression, leading to enhanced LDL receptor activity and improved cholesterol clearance that transcends the limitations of conventional pharmacological agents
2Reliability
If siRNA is used to inhibit PCSK9 gene expression, then treatment effectiveness is improved, but delivery to the liver and stability challenges arise
Solution Approach 1:
The patent constructs a composite delivery system comprising siRNA conjugated to a liver-targeting moiety. This composite structure integrates the gene-silencing function of siRNA with the targeting capability of liver-specific ligands, enabling selective delivery to hepatocytes while protecting the siRNA from degradation. The composite material approach resolves the contradiction by combining multiple functional components into a unified delivery vehicle
Solution Approach 2:
The patent introduces a liver-targeting moiety as an intermediary between the siRNA and the liver cells. This mediator component facilitates specific recognition and uptake by hepatocytes through receptor-mediated endocytosis, thereby solving the delivery challenge. The targeting moiety acts as a bridge that guides the siRNA to the intended destination while protecting it from premature degradation in circulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA conjugate exhibits high stability and specificity, achieving significant inhibition of PCSK9 gene expression, reducing LDL-c and cholesterol levels, with minimal off-target effects and toxicity, demonstrating a promising treatment for hypercholesterolemia.
Implementation Method 1
Based on the mechanism of RNA interference (RNAi), small interfering RNA (siRNA) could inhibit or block the expression of a target gene of interest in a sequence-specific manner
Data Source
AI summary
An siRNA which inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression, a pharmaceutical composition containing the siRNA, and a conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I; nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotides differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotides differences. The siRNA, pharmaceutical composition thereof and the conjugate can effectively treat and/or prevent hypercholesterolemia.